ABAdrianna L. Bartolomucci

Adrianna L. Bartolomucci

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Adrianna L. Bartolomucci has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Figure 3 from Detection of Brain Cancer Using Genome-wide Cell-free DNA Fragmentomes

    by Dimitrios Mathios, Noushin Niknafs, Akshaya V. Annapragada, Ernest J. Bobeff, Elaine J. Chiao, Kavya Boyapati, Keerti Boyapati, Sarah Short, Adrianna L. Bartolomucci, Stephen Cristiano, et al.

    Survival analyses of patients with molecularly defined untreated GBM using ARTEMIS–DELFI model components. A, The horizontal axis indicates the classifier score cutoff used to dichotomize the GBM patient cohort to low- and high-score categories. The vertical axis indicates the P value of the univariate survival analysis of the Cox proportional hazard ratios for each ARTEMIS–DELFI submodel at all evaluated score cutoffs. Each submodel of the ARTEMIS–DELFI model is represented with a different color. Kaplan–Meier survival analyses of the GBM cohort for the chromosomal arm model (B) and the epigenetic model (C) both at a score cutoff of 0.75. P values are calculated based on the log-rank test, and the estimated HR and 95% CI are shown. TE, transposable element, SINE, short interspersed nuclear elements, LINE, long interspersed nuclear elements.

  • Open Access

    Table 1 from Detection of Brain Cancer Using Genome-wide Cell-free DNA Fragmentomes

    by Dimitrios Mathios, Noushin Niknafs, Akshaya V. Annapragada, Ernest J. Bobeff, Elaine J. Chiao, Kavya Boyapati, Keerti Boyapati, Sarah Short, Adrianna L. Bartolomucci, Stephen Cristiano, et al.

    Patient characteristics for the discovery and validation cohorts.

  • Open Access

    Supplementary Tables S1-S7 from Detection of Brain Cancer Using Genome-wide Cell-free DNA Fragmentomes

    by Dimitrios Mathios, Noushin Niknafs, Akshaya V. Annapragada, Ernest J. Bobeff, Elaine J. Chiao, Kavya Boyapati, Keerti Boyapati, Sarah Short, Adrianna L. Bartolomucci, Stephen Cristiano, et al.

    Supplementary Table S1. Clinical information, sequencing statistics, and ARTEMIS-DELFI scores for cfDNA analyses in Discovery cohort. Supplementary Table S2. Clinical information, sequencing statistics, and ARTEMIS-DELFI scores for cfDNA analyses in Validation cohort. Supplementary Table S3. Summary of mutations detected by plasma-based targeted sequencing panel. Supplementary Table S4. Correlation of TF expression between GBM and other tumor types. Supplementary Table S5. Summary of complete blood count for patients with gliomas or non-neoplastic neurological conditions. Supplementary Table S6. Summary of ChIP-Seq peaks used in DECIFER analysis. Supplementary Table S7. Correlation of TFBS relative coverage differences with expression differences between tumor/cell types and whole blood.

  • Open Access

    Supplementary Figures S1-S10 from Detection of Brain Cancer Using Genome-wide Cell-free DNA Fragmentomes

    by Dimitrios Mathios, Noushin Niknafs, Akshaya V. Annapragada, Ernest J. Bobeff, Elaine J. Chiao, Kavya Boyapati, Keerti Boyapati, Sarah Short, Adrianna L. Bartolomucci, Stephen Cristiano, et al.

    Supplementary Figure S1. Schematic representation of the Ensemble model architecture used for brain cancer prediction. Supplementary Figure S2. Feature importance of the ARTEMIS-DELFI classifier by feature family. Supplementary Figure S3. ARTEMIS-DELFI score distribution across genomic library batch preparation. Supplementary Figure S4. Correlation of brain tumor size with ARTEMIS-DELFI scores. Supplementary Figure S5. ARTEMIS-DELFI scores correlate with Ki-67 proliferation indices in tumor samples. Supplementary Figure S6. Fragment length cumulative distributions of cfDNA in brain tumor patients by mutation type. Supplementary Figure S7. Schematic representation of the DECIFER methodology. Supplementary Figure S8. Heatmap representation of TF RNA expression levels by tissue type. Supplementary Figure S9. DECIFER correlation plots from the Discovery and the Validation cohorts with different tumor and tissue types. Supplementary Figure S10. Modelling the potential implementation of ARTEMIS-DELFI in the workup of headaches for brain tumors.

  • Open Access

    Figure 4 from Detection of Brain Cancer Using Genome-wide Cell-free DNA Fragmentomes

    by Dimitrios Mathios, Noushin Niknafs, Akshaya V. Annapragada, Ernest J. Bobeff, Elaine J. Chiao, Kavya Boyapati, Keerti Boyapati, Sarah Short, Adrianna L. Bartolomucci, Stephen Cristiano, et al.

    CfDNA fragmentation and mutations in plasma of patients with HGGs. A, The table shows the number and percentage of patients analyzed and detected with the ARTEMIS–DELFI assay, the tumor-guided mutational panel approach, or both. B, Histogram representation of the sensitivity of HGG detection by the mutation panel or the ARTEMIS–DELFI approach. The score threshold corresponding to 90% specificity is applied to determine the samples detected by ARTEMIS–DELFI approach. The analytical specificity of the tumor-informed mutation panel assay is 99.9%. C, Fragment length distribution of tumor-specific mutant fragments vs. fragments with no mutations, germline mutations or known clonal hematopoiesis of indeterminate potential (CHIP) mutations. Tumor-specific mutations are residing in shorter fragments than wild-type (WT) or nontumor mutant fragments (median length of 146 bp vs. 167 bp, Wilcoxon P < 0.0001).

  • Open Access

    Figure 2 from Detection of Brain Cancer Using Genome-wide Cell-free DNA Fragmentomes

    by Dimitrios Mathios, Noushin Niknafs, Akshaya V. Annapragada, Ernest J. Bobeff, Elaine J. Chiao, Kavya Boyapati, Keerti Boyapati, Sarah Short, Adrianna L. Bartolomucci, Stephen Cristiano, et al.

    ARTEMIS–DELFI performance for detection of brain cancers. ARTEMIS–DELFI score distribution across noncancer individuals and patients with brain tumor, stratified by grade and histology, in the discovery cohort. A, The boxplot shows the median ARTEMIS–DELFI score and the IQR with the individual sample values overlaid as dots. The noncancer neurologic controls, although overall exhibiting low ARTEMIS–DELFI scores, have a higher score than the screening population group (median score of 0.25 vs. 0.11; P < 0.0001). The noncancer cases with or without neurologic conditions have a lower ARTEMIS–DELFI score compared with brain tumor cases, and there is an incremental increase in the ARTEMIS–DELFI score between the LGGs (median score of 0.46) and HGGs (median score of 0.71). Within primary brain tumors, the highest median DELFI score is observed in GBMs (median score 0.72). Metastatic brain tumors (including lung, breast, ovarian, melanoma, and kidney cancers) have a high score (median of 0.86). The center line in the boxplots represents the median, the top limit of the boxplots represents the third quantile (75th percentile), the bottom limit of the boxplots represents the first quantile (25th percentile), the top whiskers is the maximum value of the data that are within 1.5 times the IQR over the 75th percentile, and the bottom whisker is the minimum value of the data that are within 1.5 times the IQR under the 25th percentile. Rec, recurrent. B, ROC analyses of the overall discovery cohort as well as by grade. The faded gray vertical lines in the ROC figures represents a 95% and 90% specificity as decision boundaries. C, The boxplot shows the median ARTEMIS–DELFI score and the IQR with the individual sample values overlaid as dots in the validation cohort. The noncancer neurologic controls exhibit a low ARTEMIS–DELFI score (median of 0.11), with gliomas (median of 0.70) and brain metastases (median of 0.86) showing elevated scores similar to our discovery cohort. D, Analysis of an ARTEMIS–DELFI fixed model and score cutoff of 0.30 determined from the discovery cohort was applied in the validation cohort. The performance of this classifier in the independent cohort was similar to the discovery cohort in both specificity (left) and sensitivity (right). The number of samples in the discovery and validation sets are indicated in the labels of the horizontal axis. The intervals presented reflect a 90% CI.

  • Open Access

    Figure 5 from Detection of Brain Cancer Using Genome-wide Cell-free DNA Fragmentomes

    by Dimitrios Mathios, Noushin Niknafs, Akshaya V. Annapragada, Ernest J. Bobeff, Elaine J. Chiao, Kavya Boyapati, Keerti Boyapati, Sarah Short, Adrianna L. Bartolomucci, Stephen Cristiano, et al.

    Origins of cfDNA fragmentation in HGGs based on DECIFER analyses. A, The horizontal axis shows the quantile of number of TFBSs (numbers closer to 0 include a greater number of TFs with a lower number of BSs, and numbers closer to 1 include fewer TFs with a larger number of BSs), and the vertical axis shows the level of Pearson R correlation between the effect size of relative coverage in TFBSs of patients with HGGs vs. noncancer individuals and the effect size of TF RNA expression of several tumor types vs. whole blood. The vertical axis contains all available data. This correlation is calculated and depicted across the full array of number of TFBS quantiles from 0 to 1. Each tumor type is color-coded. B, This panel is a similar graph to (A) that includes immune cell subpopulations, brain tumor tissue, brain cells, and other cancers, including liver hepatocellular carcinoma (LIHC) and lung adenocarcinoma (LUAD). C, Box plots represent the % of immune subpopulations in noncancer, LGGs, and HGGs based on complete blood count differential analysis. The center line in the boxplots represents the median, the top limit of the boxplots represents the third quantile (75th percentile), the bottom limit of the boxplots represents the first quantile (25th percentile), the top whiskers is the maximum value of the data that are within 1.5 times the IQR over the 75th percentile, and the bottom whisker is the minimum value of the data that are within 1.5 times the IQR under the 25th percentile. AML, acute myeloid leukemia; BRCA, Breast invasive carcinoma; NNNC, nonneoplastic neurologic control; BLCA, bladder urothelial carcinoma; COAD, colon adenocarcinoma; KIRC, kidney renal cell carcinoma; LUSC, lung squamous cell carcinoma; OV, ovarian serous cystadenocarcinoma; PRAD, prostate adenocarcinoma; STAD, stomach adenocarcinoma.

  • Open Access

    Figure 1 from Detection of Brain Cancer Using Genome-wide Cell-free DNA Fragmentomes

    by Dimitrios Mathios, Noushin Niknafs, Akshaya V. Annapragada, Ernest J. Bobeff, Elaine J. Chiao, Kavya Boyapati, Keerti Boyapati, Sarah Short, Adrianna L. Bartolomucci, Stephen Cristiano, et al.

    Schematic overview of the study. A, Schematic overview of the study design, including cohort selection and experimental and statistical approaches. TE, transposable element, SINE, short interspersed nuclear elements, LINE, long interspersed nuclear elements, PNS, peripheral nervous system. B, Schematic overview of the systemic and local pathophysiologic alterations in HGGs relevant to cfDNA fragmentation and liquid biopsies. HGGs establish a systemic and local immune-suppressive environment that leads to systemic lymphopenia and infiltration of myeloid-derived suppressor cells in the tumor microenvironment. Apoptotic lymphocytes release cfDNA in the circulation, increasing the contribution of lymphocytes to the total pool of cfDNA fragments compared with individuals without cancer. In the local microenvironment, the blood–brain barrier (BBB) is broken down in the tumor, thus allowing nucleosomal DNA from apoptotic tumor cells and other supporting cells to exit into the circulation.


  • Open Access

    Detection of Brain Cancer Using Genome-wide Cell-free DNA Fragmentomes

    by Dimitrios Mathios, Noushin Niknafs, Akshaya V. Annapragada, Ernest J. Bobeff, Elaine J. Chiao, Kavya Boyapati, Keerti Boyapati, Sarah Short, Adrianna L. Bartolomucci, Stephen Cristiano, et al.

    Diagnostic delays in patients with brain cancer are common and can impact patient outcome. Development of a blood-based assay for detection of brain cancers could accelerate brain cancer diagnosis. In this study, we analyzed genome-wide cell-free (cfDNA) fragmentomes, including fragmentation profiles and repeat landscapes, from the plasma of individuals with (n = 148) or without (n = 357) brain cancer. Machine learning analyses of cfDNA fragmentome features detected brain cancer across all-grade gliomas (AUC = 0.90; 95% confidence interval, 0.87–0.93), and these results were validated in an independent prospectively collected cohort. cfDNA fragmentome changes in patients with gliomas represented a combination of fragmentation profiles from glioma cells and altered white blood cell populations in the circulation. These analyses reveal the properties of cfDNA in patients with brain cancer and open new avenues for noninvasive detection of these individuals. Significance: Brain cancer is one of the deadliest and most challenging cancers to detect with liquid biopsy approaches in blood, hampering efforts for earlier noninvasive diagnosis. We have developed a machine learning genome-wide cfDNA fragmentation method that provides a sensitive and accessible approach for brain cancer detection.


  • Open Access

    Supplementary Figures from Early Detection of Ovarian Cancer Using Cell-Free DNA Fragmentomes and Protein Biomarkers

    by Jamie E. Medina, Akshaya V. Annapragada, Pien Lof, Sarah Short, Adrianna L. Bartolomucci, Dimitrios Mathios, Shashikant Koul, Noushin Niknafs, Michaël Noë, Zachariah H. Foda, et al.

    Supplementary Figure S1. Evaluation of screening model DELFI-Pro scores and comorbidities in individuals without cancer. Supplementary Figure S2. DELFI-Pro score evaluation in available clinical characteristics of patients with cancer. Supplementary Figure S3. Stability analysis across fold repeats and collection source. Supplementary Figure S4. Detection of ovarian cancer subtypes using DELFI-Pro screening model. Supplementary Figure S5. ROC analyses of asymptomatic individuals in the using screening or diagnostic models in the Discovery Cohort. Supplementary Figure S6. Performance of ichorCNA and median cfDNA fragment lengths in the Discovery Cohorts. Supplementary Figure S7. Detection of ovarian cancer subtypes using DELFI-Pro at high specificity. Supplementary Figure S8. Genome-wide fragmentation profiles are altered in patients in the Validation Cohort with ovarian cancer. Supplementary Figure S9. Analyses of chromosomal changes in Discovery and Validation cohorts. Supplementary Figure S10. Performance of DELFI-Pro for detection of ovarian cancer in the Validation Cohort. Supplementary Figure S11. Correlation of rank ordered DELFI-Pro scores for the Screening and Diagnostic models. Supplementary Figure S12. Assessment of DELFI-Pro in women with benign lesions. Supplementary Figure S13. Performance of DELFI-Pro for distinguishing ovarian cancer from benign masses. Supplementary Figure S14. Performance of DELFI-Pro for distinguishing ovarian cancer subtypes from benign masses. Supplementary Figure S15. Performance of DELFI-Pro for distinguishing ovarian cancer subtypes from benign masses in Validation Cohort. Supplementary Figure S16. Evaluation of overall tumor burden using the sum of reported lesion diameters. Supplementary Figure S17. Evaluation of CA1-25 and HE4 blood concentrations measured at different centers.